Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Axol Bioscience, a leading pluripotent stem cell technology provider for drug discovery has signed an […]
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics, a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced […]
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the […]
Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting
Promontory Therapeutics, a clinical-stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data […]
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Pfizer has announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has […]
Hansa Announces Global Pivotal Phase 3 Trial in Anti-GBM Disease
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced the first […]
Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial
Genome Medical, the leading telehealth provider of genetic services and solutions, is teaming up with […]
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more